Skip to main content
Top
Published in: Lung 5/2010

01-10-2010

Angiogenic Activity of Sera from Extrinsic Allergic Alveolitis Patients in Relation to Clinical, Radiological, and Functional Pulmonary Changes

Authors: Tadeusz M. Zielonka, Urszula Demkow, Małgorzata Filewska, Beata Bialas, Katarzyna Zycinska, Elzbieta Radzikowska, Andrzej K. Wardyn, Ewa Skopinska-Rozewska

Published in: Lung | Issue 5/2010

Login to get access

Abstract

Extrinsic allergic alveolitis (EAA) caused by inhaled organic environmental allergens can progress to a fibrotic end-stage lung disease. Neovascularization plays an important role in pathogenesis of pulmonary fibrosis. The aim of this study was to assess the effect of sera from EAA patients on the angiogenic capability of normal peripheral human mononuclear cells (MNC) in relation to the clinical, radiological, and functional changes. The study population consisted of 30 EAA patients and 16 healthy volunteers. Routine pulmonary function tests were undertaken using ERS standards. As an angiogenic test, leukocyte-induced angiogenesis assay according to Sidky and Auerbach was used. Compared with sera from healthy volunteers, sera from our EAA patients significantly stimulated angiogenesis (P < 0.001). However, sera from healthy donors also stimulated angiogenesis compared to PBS (P < 0.001). No correlation was found between serum angiogenic activity and clinical symptoms manifested by evaluated patients. A decrease in DLco and in lung compliance in EAA patients was observed but no significant correlation between pulmonary functional tests and serum angiogenic activity measured by the number of microvessels or an angiogenesis index was found. However, the proangiogenic effect of sera from EAA patients differed depending on the stage of the disease and was stronger in patients with fibrotic changes. The present study suggests that angiogenesis plays a role in the pathogenesis of EAA. It could be possible that the increase in the angiogenic activity of sera from EAA patients depends on the phase of the disease.
Literature
1.
go back to reference Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515CrossRefPubMed Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515CrossRefPubMed
2.
go back to reference Chen Y, Nakashima Y, Shiraishi S, Nakagawa K, Sueishi N (1999) Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioscler Thromb Vasc Biol 19:131–139PubMed Chen Y, Nakashima Y, Shiraishi S, Nakagawa K, Sueishi N (1999) Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioscler Thromb Vasc Biol 19:131–139PubMed
3.
go back to reference Paleolog EM, Miotla JM (1998) Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 2:295–307CrossRefPubMed Paleolog EM, Miotla JM (1998) Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 2:295–307CrossRefPubMed
4.
go back to reference Tzouvelekis A, Anevlavis S, Bouros D (2006) Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir Res 7:82CrossRefPubMed Tzouvelekis A, Anevlavis S, Bouros D (2006) Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir Res 7:82CrossRefPubMed
5.
go back to reference Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845CrossRefPubMed Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845CrossRefPubMed
6.
go back to reference Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM (1999) IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 163:5686–5692PubMed Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM (1999) IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 163:5686–5692PubMed
7.
go back to reference Nakayama S, Mukae H, Ishii H, Kakugawa T, Sugiyama K, Sakamoto N, Fujii T, Kadota J, Kohno S (2005) Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Respir Med 99:1145–1151CrossRefPubMed Nakayama S, Mukae H, Ishii H, Kakugawa T, Sugiyama K, Sakamoto N, Fujii T, Kadota J, Kohno S (2005) Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Respir Med 99:1145–1151CrossRefPubMed
8.
go back to reference Girard M, Israël-Assayag E, Cormier Y (2004) Pathogenesis of hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol 4:93–98CrossRefPubMed Girard M, Israël-Assayag E, Cormier Y (2004) Pathogenesis of hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol 4:93–98CrossRefPubMed
9.
go back to reference Bourke SJ, Dalphin JC, Boyd G, McSharry C, Baldwin CI, Calvert JE (2001) Hypersensitivity pneumonitis: current concepts. Eur Respir J 18(Suppl 32):81s–92s Bourke SJ, Dalphin JC, Boyd G, McSharry C, Baldwin CI, Calvert JE (2001) Hypersensitivity pneumonitis: current concepts. Eur Respir J 18(Suppl 32):81s–92s
10.
go back to reference Yamasaki H, Ando M, Brazer W, Center DM, Cruikshank WW (1999) Polarized type 1 cytokine profile in bronchoalveolar lavage T cells of patients with hypersensitivity pneumonitis. J Immunol 163:3516–3523PubMed Yamasaki H, Ando M, Brazer W, Center DM, Cruikshank WW (1999) Polarized type 1 cytokine profile in bronchoalveolar lavage T cells of patients with hypersensitivity pneumonitis. J Immunol 163:3516–3523PubMed
11.
go back to reference Navarro C, Mendoza F, Barrera L, Segura-Valdez L, Gaxiola M, Páramo I, Selaman M (2002) Up-regulation of L-selectin and E-selectin in hypersensitivity pneumonitis. Chest 121:354–360CrossRefPubMed Navarro C, Mendoza F, Barrera L, Segura-Valdez L, Gaxiola M, Páramo I, Selaman M (2002) Up-regulation of L-selectin and E-selectin in hypersensitivity pneumonitis. Chest 121:354–360CrossRefPubMed
12.
go back to reference Nguyen M, Strubel NA, Bischoff J (1993) A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365:267–269CrossRefPubMed Nguyen M, Strubel NA, Bischoff J (1993) A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365:267–269CrossRefPubMed
13.
go back to reference Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Y (2003) Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 168:952–958CrossRefPubMed Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Y (2003) Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 168:952–958CrossRefPubMed
14.
go back to reference Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1993) Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 6(Suppl 16):5–40 Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1993) Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 6(Suppl 16):5–40
15.
go back to reference Sidky YA, Auerbach R (1975) Lymphocyte-induced angiogenesis: a quantitative and sensitive assay for the graft-vs.-host reaction. J Exp Med 141:1084–1100CrossRefPubMed Sidky YA, Auerbach R (1975) Lymphocyte-induced angiogenesis: a quantitative and sensitive assay for the graft-vs.-host reaction. J Exp Med 141:1084–1100CrossRefPubMed
16.
go back to reference Zielonka TM, Demkow U, Białas B, Filewska M, Życińska K, Radzikowska E, Szopinski J, Skopińska-Różewska E (2007) Modulatory effect of sera from sarcoidosis patients on mononuclear cells-induced angiogenesis. J Physiol Pharmacol 58(Suppl 5):753–766PubMed Zielonka TM, Demkow U, Białas B, Filewska M, Życińska K, Radzikowska E, Szopinski J, Skopińska-Różewska E (2007) Modulatory effect of sera from sarcoidosis patients on mononuclear cells-induced angiogenesis. J Physiol Pharmacol 58(Suppl 5):753–766PubMed
17.
go back to reference Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. FASEB J 11:457–465PubMed Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. FASEB J 11:457–465PubMed
18.
go back to reference Forst LS, Abraham J (1993) Hypersensitivity pneumonitis presenting as sarcoidosis. Br J Ind Med 50:497–500PubMed Forst LS, Abraham J (1993) Hypersensitivity pneumonitis presenting as sarcoidosis. Br J Ind Med 50:497–500PubMed
19.
go back to reference Meyer KC, Kaminski MJ, Calhoun WJ, Auerbach R (1989) Studies of bronchoalveolar lavage cells and fluids in pulmonary sarcoidosis. I. Enhanced capacity of bronchoalveolar lavage cells from patients with pulmonary sarcoidosis to induce angiogenesis in vivo. Am Rev Respir Dis 140:1446–1449PubMed Meyer KC, Kaminski MJ, Calhoun WJ, Auerbach R (1989) Studies of bronchoalveolar lavage cells and fluids in pulmonary sarcoidosis. I. Enhanced capacity of bronchoalveolar lavage cells from patients with pulmonary sarcoidosis to induce angiogenesis in vivo. Am Rev Respir Dis 140:1446–1449PubMed
20.
go back to reference Tolnay E, Kuhnen C, Voss B, Wiethege T, Müller KM (1998) Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis. Virchows Arch 432:61–65CrossRefPubMed Tolnay E, Kuhnen C, Voss B, Wiethege T, Müller KM (1998) Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis. Virchows Arch 432:61–65CrossRefPubMed
21.
go back to reference Agostini C, Cassatella M, Zambello R, Trentin L, Gasperini S, Perin A, Piazza F, Siviero M, Facco M, Dziejman M, Chilosi M, Qin S, Luster AD, Semenzato G (1998) Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 161:6413–6420PubMed Agostini C, Cassatella M, Zambello R, Trentin L, Gasperini S, Perin A, Piazza F, Siviero M, Facco M, Dziejman M, Chilosi M, Qin S, Luster AD, Semenzato G (1998) Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 161:6413–6420PubMed
22.
go back to reference Sekiya M, Ohwada A, Miura K, Takahashi S, Fukuchi Y (2003) Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 181:259–265CrossRefPubMed Sekiya M, Ohwada A, Miura K, Takahashi S, Fukuchi Y (2003) Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 181:259–265CrossRefPubMed
23.
go back to reference Navarro C, Ruiz V, Gaxiola M, Carrillo G, Selman M (2003) Angiogenesis in hypersensitivity pneumonitis. Arch Physiol Biochem 111:365–368CrossRefPubMed Navarro C, Ruiz V, Gaxiola M, Carrillo G, Selman M (2003) Angiogenesis in hypersensitivity pneumonitis. Arch Physiol Biochem 111:365–368CrossRefPubMed
24.
go back to reference Pardo A, Barrios R, Gaxiola M, Segura-Valdez L, Carrillo G, Estrada A, Mejía M, Selman M (2000) Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis. Am J Respir Crit Care Med 161:1698–1704PubMed Pardo A, Barrios R, Gaxiola M, Segura-Valdez L, Carrillo G, Estrada A, Mejía M, Selman M (2000) Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis. Am J Respir Crit Care Med 161:1698–1704PubMed
25.
go back to reference Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237–268PubMed Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237–268PubMed
26.
go back to reference Wagner EM, Sanchez J, McClintock JY, Jenkins J, Moldobaeva A (2008) Inflammation and ischemia-induced lung angiogenesis. Am J Physiol Lung Cell Mol Physiol 294(2):L351–L357CrossRefPubMed Wagner EM, Sanchez J, McClintock JY, Jenkins J, Moldobaeva A (2008) Inflammation and ischemia-induced lung angiogenesis. Am J Physiol Lung Cell Mol Physiol 294(2):L351–L357CrossRefPubMed
27.
go back to reference Renzoni EA, Walsh DA, Salmon M, Wells AU, Sestini P, Nicholson AG, Veeraraghavan S, Bishop AE, Romanska HM, Pantelidis P, Black CM, du Bois RM (2003) Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 167:438–443CrossRefPubMed Renzoni EA, Walsh DA, Salmon M, Wells AU, Sestini P, Nicholson AG, Veeraraghavan S, Bishop AE, Romanska HM, Pantelidis P, Black CM, du Bois RM (2003) Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 167:438–443CrossRefPubMed
28.
go back to reference Keane MP, Arenberg DA, Lynch JP III, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM (1997) The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159:1437–1443PubMed Keane MP, Arenberg DA, Lynch JP III, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM (1997) The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159:1437–1443PubMed
29.
go back to reference Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM (2001) ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164:2239–2242PubMed Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM (2001) ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164:2239–2242PubMed
30.
go back to reference Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK (2004) The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 116:662–668CrossRefPubMed Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK (2004) The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 116:662–668CrossRefPubMed
31.
go back to reference Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ (2004) Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 59:581–585CrossRefPubMed Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ (2004) Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 59:581–585CrossRefPubMed
32.
go back to reference Zielonka TM, Demkow U, Filewska M, Białas B, Korczyński P, Szopiński J, Soszka A, Skopińska-Różewska E (2007) Angiogenic activity of sera from interstitial lung diseases patients to IL-6, IL-8, IL-12 and TNFα serum level. Centr Eur J Immunol 32:53–60 Zielonka TM, Demkow U, Filewska M, Białas B, Korczyński P, Szopiński J, Soszka A, Skopińska-Różewska E (2007) Angiogenic activity of sera from interstitial lung diseases patients to IL-6, IL-8, IL-12 and TNFα serum level. Centr Eur J Immunol 32:53–60
Metadata
Title
Angiogenic Activity of Sera from Extrinsic Allergic Alveolitis Patients in Relation to Clinical, Radiological, and Functional Pulmonary Changes
Authors
Tadeusz M. Zielonka
Urszula Demkow
Małgorzata Filewska
Beata Bialas
Katarzyna Zycinska
Elzbieta Radzikowska
Andrzej K. Wardyn
Ewa Skopinska-Rozewska
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Lung / Issue 5/2010
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-010-9228-5

Other articles of this Issue 5/2010

Lung 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.